Key Drivers
- Strong liquidity
- Persistent losses
- Stretched valuation
AIAI Summary
MESO should be reframed as a commercialization‑stage cell‑therapy whose near‑term valuation will be decided by execution on Ryoncil® sales and cash runway—monitor monthly Ryoncil® sales cadence, payer uptake, cash burn and the undrawn $50M tranche, because strong ~70% gross margins can quickly de‑risk the story but missed sales or the need for dilutive financing would prompt sharp multiple compression.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Persistent losses
- •Stretched valuation
MESO has strong near-term liquidity and very high gross margins but is undermined by persistent large operating losses, negative free cash flow, low asset efficiency, heavy intangibles, and a stretched valuation.
Price Behavior
Key Price Behavior Insights:
- •Short-term downtrend
- •Below moving average
- •Narrow consolidation
Over last month MESO fell ~15% to $14.36 and trades ~6.7% below its last-month 21-day average (~$15.39), indicating a short-term downtrend with support near $14.36–$14.55 and resistance at $15.4–$15.9 (near-term) and $16.7–$16.9 (stronger).
~15% decline from $16.88 to $14.36 over last month indicating elevated short-term volatility
Sentiment & News
Key News Insights:
- •Ryoncil revenue
- •Inaugural R&D Day
- •Leadership hire
Mesoblast is advancing Ryoncil-backed clinical/commercial programs and leadership/R&D initiatives but faces near-term stock pressure after a reiterated sell rating and recent gap-down.
Ongoing commercial and development momentum supports medium-term upside, but near-term sentiment and sell-side pressure may constrain the share price
Similar Companies in Healthcare
Other companies in the same sector with AI ratings